The Lancet. HaematologyHumansMiddle AgedMaleAdultFemale
IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.
Qianwen Xu, Yugang Guo, Min Gao, Lei Xue, Hui Xu, Hui Li, Xuhan Zhang, Chongling Liu, Youjia Li, Qian Chen, Jingjing Ren, Karthik Sathiyanadan, Yongxian Hu, Li Tang, He Huang
Published: 202510.1016/S2352-3026(25)00253-4
Abstract
BACKGROUND: Although chimeric antigen receptor (CAR) T-cell therapy has improved clinical outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, treatment resistance and relapse after remission driven by CAR T-cell dy…
Preview only. Read the full abstract at the source